The first participants have been vaccinated in a Phase 1 clinical trial of an experimental HIV vaccine that utilizes Moderna's mRNA technology, the company announced.
The trial, titled IAVI G002, is being conducted in partnership with IAVI, a nonprofit scientific research organization. It is testing a vaccine that delivers HIV-specific antigens to the body with the goal of inducing an immune response. These antigens were initially developed by researchers at IAVI and Scripps Research, led by Dr. William Schief.
The new trial, funded in part by the Bill & Melinda Gates Foundation, will follow 56 HIV-negative adult participants, with the goal of studying both the safety and efficacy of the vaccine. Forty-eight of the volunteers will receive at least one dose of the primary vaccine, 32 of which will also receive the booster. The remaining eight will receive the booster vaccine alone.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Moderna launches clinical trial for HIV vaccine that uses mRNA technology
Read more »
Moderna starts HIV vaccine trialsEarly Phase 1 trials of an HIV vaccine have started, Moderna announced Thursday. The vaccine under development uses mRNA, or messenger RNA, to provoke an immune response.
Read more »
Study Finds Cancer Drug May Also Flush Out Dormant HIVPart of the reason HIV is so hard to cure is that it hides in a state of hibernation inside long-lived immune cells.
Read more »
Moderna launches clinical trial for HIV vaccine that uses mRNA technology
Read more »
Moderna starts HIV vaccine trialsEarly Phase 1 trials of an HIV vaccine have started, Moderna announced Thursday. The vaccine under development uses mRNA, or messenger RNA, to provoke an immune response.
Read more »
Children Under 5-Years-Old May Soon Be Eligible For COVID VaccineClinical trials on little kids are underway on a two-dose vaccine and a three-dose shot. The goal is to prevent severe disease.
Read more »